In part 2 of this interview with Frederick L. Locke, MD, lead investigator on the phase 1 ALPHA (NCT03939026) and ALPHA2 (NCT04416984) trials of allogeneic chimeric antigen receptor T-cell therapy ...
Which of the statements below about histology of fetal and neonatal alloimmune thrombocytopenia (FNAIT) are correct? Select one of the options for each question, then submit your answers to see how ...
Laboratory of Natural and Targeted Small Molecule Drugs, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy ...
The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback